NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

HLUNB.DK

44.56

+1.41%↑

AMBUB.DK

66.35

+3.67%↑

Home・Listă Acțiuni・Zealand Pharma A-S

Zealand Pharma A-S

Închisă

332 10.96

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

328.7

Maxim

336.8

Indicatori cheie
By Trading Economics
Venit	-15M -394M
Vânzări	-35M 34M
P/E Medie Sector	3.509 49.888
EPS	-5.58
Marjă de profit	-1,158.824
Angajați	544
EBITDA	-26M -529M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+25.15% upside

Dividende
By Dow Jones
Următoarele câștiguri	13 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	919M 22B
Deschiderea anterioară	321.04
Închiderea anterioară	332

Zealand Pharma A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mar. 2026, 09:24 UTC

Principalele dinamici ale pieței

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

1 oct. 2025, 08:54 UTC

Principalele dinamici ale pieței

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

6 mar. 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

Comparație

Modificare preț

Zealand Pharma A-S Așteptări

Obiectiv de preț

By TipRanks

25.15% sus

Prognoză pe 12 luni

Medie 270.582 DKK 25.15%

Maxim 270.568 DKK

Minim 270.568 DKK

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruZealand Pharma A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Zealand Pharma A-S - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.